Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 8911359.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer. The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed. All tumors were grade 3 or 4 transitional cell carcinoma. Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease. Of the 6 patients who underwent early cystectomy 4 were alive at 24 to 111 months. The remaining patient with extensive cancer underwent partial cystectomy for palliation and died 3 months later. Cyclophosphamide associated bladder tumor is an aggressive disease. However, long-term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease, even when noninvasive.
Medical subject headings
- Carcinoma, Transitional Cell
- Cyclophosphamide
- Urinary Bladder Neoplasms